Tenax Therapeutics Faces Setback After Late-Stage Trial Failure
Tenax Therapeutics disclosed that its experimental heart drug failed to meet the primary endpoint in a late-stage study, signaling a setback for its lead program. The negative readout raises questions about pipeline viability and capitalization needs, likely pressuring shares in the near term and potentially delaying any strategic milestones.
View signal analysis